Axelar AB is a Swedish biotechnology company that focuses
its activities on research related to the insulin-like growth
factor-1 (IGF-1) receptor inhibitors and their applications
in important human diseases, especially cancer.
Axelar’s overall objective is to develop innovative
small-molecule compounds that inhibit the IGF-1 receptor for
treatment of IGF-1 receptor-dependent diseases where a significant
unmet medical need still exists.
Axelar aspires to move these compounds into the clinic and
then to enter partnerships that ensures global development
and commercialization. |
|
Latest news
Press release November 13, 2009
Axelar AB Presents the New Anticancer Agent AXL1717 at The
AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics in Boston, Massachusetts, USA
Press release May 06, 2009
Successful Phase I/II Clinical Trial Results from Cancer Patients
Treated with Anticancer Drug from Axelar AB
Press release June 17, 2008
Axelar initiates phase I/II clinical trial on cancer patients
with the new anti-cancer drug AXL1717
|